Pricing
  1. JP-listed companies
  2. TAKARA BIO INC.
  3. Financials
  4. Revenue growth (%)

TAKARA BIO INC.【JP:4974】

Market cap
¥138.1B
P/E ratio
-15.3x
Takara Bio develops and manufactures biotechnology products including research reagents, PCR instruments, and gene therapy treatments for universities, research institutions, and companies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Mar 31, 20253.5-107.96%
Mar 31, 2024-44.3-387.30%
Mar 31, 202315.4-67.10%
Mar 31, 202246.9+40.71%
Mar 31, 202133.3-1036.24%
Mar 31, 2020-3.6-132.60%
Mar 31, 201910.9+9.20%
Mar 31, 201810-940.34%
Mar 31, 2017-1.2-108.22%
Mar 31, 201614.5+67.79%
Mar 31, 20158.6-46.89%
Mar 31, 201416.3+222.42%
Mar 31, 20135

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)